A detailed history of Barclays PLC transactions in Amgen Inc stock. As of the latest transaction made, Barclays PLC holds 351,300 shares of AMGN stock, worth $101 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
351,300
Previous 2,321,848 84.87%
Holding current value
$101 Million
Previous $748 Million 84.87%
% of portfolio
0.03%
Previous 0.2%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$309.38 - $337.38 $136 Million - $148 Million
438,293 Added 23.27%
2,321,848 $748 Million
Q2 2024

Aug 14, 2024

SELL
$262.75 - $319.31 $646 Million - $785 Million
-2,459,106 Reduced 56.63%
1,883,555 $589 Million
Q1 2024

May 15, 2024

BUY
$268.87 - $324.56 $384 Million - $463 Million
1,426,434 Added 48.91%
4,342,661 $1.23 Billion
Q4 2023

Feb 15, 2024

BUY
$255.7 - $288.46 $354 Million - $400 Million
1,385,762 Added 90.55%
2,916,227 $840 Million
Q3 2023

Nov 07, 2023

SELL
$218.65 - $271.46 $34.9 Million - $43.4 Million
-159,722 Reduced 9.45%
1,530,465 $411 Million
Q2 2023

Aug 03, 2023

BUY
$214.27 - $253.37 $191 Million - $226 Million
890,242 Added 111.29%
1,690,187 $375 Million
Q1 2023

May 04, 2023

SELL
$225.79 - $275.2 $208 Million - $254 Million
-921,588 Reduced 53.53%
799,945 $193 Million
Q4 2022

Feb 13, 2023

BUY
$229.03 - $291.01 $164 Million - $208 Million
714,274 Added 70.91%
1,721,533 $452 Million
Q3 2022

Nov 03, 2022

BUY
$224.46 - $253.15 $36.7 Million - $41.4 Million
163,726 Added 19.41%
1,007,259 $227 Million
Q2 2022

Aug 12, 2022

SELL
$230.71 - $256.74 $97 Million - $108 Million
-420,372 Reduced 33.26%
843,533 $205 Million
Q1 2022

May 16, 2022

SELL
$219.27 - $242.57 $388 Million - $429 Million
-1,769,873 Reduced 58.34%
1,263,905 $306 Million
Q4 2021

Feb 14, 2022

BUY
$198.88 - $227.6 $196 Million - $224 Million
984,406 Added 48.03%
3,033,778 $683 Million
Q3 2021

Nov 09, 2021

BUY
$212.27 - $248.7 $125 Million - $146 Million
586,707 Added 40.11%
2,049,372 $436 Million
Q2 2021

Aug 13, 2021

BUY
$233.58 - $259.14 $53 Million - $58.8 Million
226,790 Added 18.35%
1,462,665 $357 Million
Q1 2021

May 13, 2021

BUY
$221.91 - $258.6 $58.9 Million - $68.7 Million
265,594 Added 27.37%
1,235,875 $308 Million
Q4 2020

Feb 11, 2021

BUY
$216.38 - $257.67 $21.3 Million - $25.4 Million
98,667 Added 11.32%
970,281 $223 Million
Q3 2020

Nov 12, 2020

BUY
$234.65 - $260.95 $28.5 Million - $31.7 Million
121,433 Added 16.19%
871,614 $222 Million
Q2 2020

Aug 12, 2020

SELL
$197.81 - $242.74 $23.6 Million - $28.9 Million
-119,190 Reduced 13.71%
750,181 $177 Million
Q1 2020

May 13, 2020

SELL
$182.24 - $241.7 $109 Million - $144 Million
-596,754 Reduced 40.7%
869,371 $176 Million
Q4 2019

Feb 10, 2020

SELL
$189.21 - $243.2 $20.9 Million - $26.9 Million
-110,649 Reduced 7.02%
1,466,125 $353 Million
Q3 2019

Nov 14, 2019

SELL
$174.11 - $208.62 $69.3 Million - $83.1 Million
-398,116 Reduced 20.16%
1,576,774 $305 Million
Q2 2019

Aug 14, 2019

BUY
$166.7 - $195.41 $108 Million - $126 Million
645,704 Added 48.58%
1,974,890 $364 Million
Q1 2019

May 15, 2019

BUY
$180.87 - $203.88 $13.2 Million - $14.9 Million
73,123 Added 5.82%
1,329,186 $253 Million
Q4 2018

Feb 14, 2019

SELL
$178.4 - $208.25 $26.1 Million - $30.4 Million
-146,047 Reduced 10.42%
1,256,063 $245 Million
Q3 2018

Nov 14, 2018

SELL
$185.29 - $208.89 $1.77 Million - $1.99 Million
-9,535 Reduced 0.68%
1,402,110 $291 Million
Q2 2018

Aug 14, 2018

SELL
$166.05 - $186.51 $148 Million - $166 Million
-889,143 Reduced 38.65%
1,411,645 $261 Million
Q1 2018

May 15, 2018

BUY
$169.43 - $198.0 $129 Million - $151 Million
762,949 Added 49.61%
2,300,788 $392 Million
Q4 2017

Feb 14, 2018

BUY
$168.79 - $188.59 $56.6 Million - $63.2 Million
335,122 Added 27.86%
1,537,839 $267 Million
Q3 2017

Nov 14, 2017

BUY
$167.29 - $191.0 $201 Million - $230 Million
1,202,717
1,202,717 $224 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $154B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.